Drug Approval | November 12, 2021
Sun Pharma to introduce molnupiravir in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
